Clinical efficacy and safety of methotrexate compared with leflunomide in the treatment of rheumatoid arthritis
Open Access
- 23 December 2021
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Medicine
- Vol. 100 (51), e28285
- https://doi.org/10.1097/md.0000000000028285
Abstract
Background: Methotrexate and leflunomide are classic treatments for rheumatoid arthritis (RA), however, which is the best choice for patients of RA is still an important question clinically, and this meta-analysis is used to systematically evaluate and compare their efficacy and safety. Methods: We searched PubMed, Cochrance Library, Embase, SinoMed, China National Knowledge Infrastructure, China Science and Technology Journal Database, WanFang Data databases. The retrieval time was from the establishment to September 7, 2021. Literature screening, data extraction, and quality assessment were performed according to the Cochrane risk of bias tool. Meta-analysis of the included studies was performed using RevMan 5.3 software and Stata 12.0 software. Results: The clinical efficacy and safety of leflunomide and methotrexate are evaluated by American College of Rheumatology (ACR)20/50/70, DAS28, total effective rate, adverse reaction rate, morning stiffness, swollen joint count, tender joint count, erythrocyte sedimentation rate, C-reactive protein, and rheumatoid factor. Conclusion: The results of this meta-analysis will provide reliable evidence clinical efficacy and safety for RA. More high-quality randomized controlled trials are still needed to provide more reliable evidence for the treatment of RA. PROSPERO number: CRD42021270980Keywords
Funding Information
- National Natural Science Foundation of China (no. 81803993)
This publication has 22 references indexed in Scilit:
- Methotrexate inhibits osteoclastogenesis by decreasing RANKL-induced calcium influx into osteoclast progenitorsJournal of Bone and Mineral Metabolism, 2015
- Analysis of patents on anti-rheumatoid arthritis therapies issued in ChinaExpert Opinion on Therapeutic Patents, 2015
- Molecular Basis for Pharmacokinetics and Pharmacodynamics of Methotrexate in Rheumatoid Arthritis TherapyDrug Metabolism and Pharmacokinetics, 2014
- Safety evaluation of leflunomide in rheumatoid arthritisExpert Opinion on Drug Safety, 2013
- Inhibitory effects of leflunomide therapy on the activity of matrixmetalloproteinase-9 and the release of cartilage oligomeric matrix protein in patients with rheumatoid arthritis.2006
- The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritisCytokine, 2006
- Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytesCytokine, 2005
- Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritisBritish Journal of Clinical Pharmacology, 2005
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988